In vitro study details the increased performance and potential of CPSI’s Supercritical Nitrogen cryoablation device for the epicardial based ablation of cardiac tissue

OWEGO, NY – CPSI Biotech announced today the publication of a peer-reviewed article detailing the enhanced performance CPSI’s next generation supercritical nitrogen (SCN) cryoablation device and its potential application in the treatment of cardiac arrhythmias. The study, titled “Evaluation of a New Epicardial Cryoablation System for the Treatment of Cardiac Tachyarrhythmias”, published as an open access article in the journal Trends in Medicine (February 2, 2018, accessible free of charge at:, was a multi-institutional collaboration between researchers from CPSI and Binghamton University.

The article details developments in CPSI’s cardiac cryoablation technology platform. The study investigated the performance of the patented Supercritical Nitrogen (SCN) cryoablation system and epicardial cryoablation probe developed by CPSI. The studies, conducted using a series of heat loaded engineering and tissue models, demonstrated the ability of the system to quickly and effectively deliver an ablative dose. Commenting on the study, Dr. John M. Baust (CPSI President and Lead Scientist) stated “We have been working on a series of a next generation cryoablation devices and probes for targeting various cardiac arrhythmias for a number of years. These activities have resulted in the development of a platform of new ablation probes and catheters, the ICEolate platform, designed to support ablation of cardiac tissue using either a epicardial or endocardial approach. This specific study focused on evaluations of the epicardial cryoprobe technology. The results demonstrate that the SCN system is able to generate ablative power several fold greater than today’s commercial cryoablation systems and as such deliver a ablative dose in less than one minute in many cases.”

This study was conducted as part of CPSI’s ongoing research and technology development program which involves the development of a next generation cryoablation devices and approaches for the treatment of various disease states. Ongoing efforts continue to build upon this success and are focusing on continued development, optimization and testing of these new devices. Speaking to the broader device development program at CPSI, Baust added “while this study focused on our prototype epicardial cardiac probe, we are also actively developing linear and balloon tipped catheter technologies as part of the ICEolate platform to support endocardial based procedures. The power of the patented cryoablation engines that CPSI’s engineers have developed has opened a number of doors for advanced treatment for various diseases. We are excited to take the next steps with this technology.” With development underway, CPSI is poised to embark down the commercialization path. To this end, Baust commented “We are actively seeking investors and partners through a variety of mechanisms to join our team to bring this potentially lifesaving technology platform to the market.”

Click Here to read the full Press Release: New Cryoablation Device Targets Enhanced Treatment of Cardiac Arrhythmias 

View other CPSI Biotech news and recent patent announcements